FDA Determines Regulatory Review Period for DAKLINZA Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the patent extension of DAKLINZA, a human drug product, following a submission to the U.S. Patent and Trademark Office (USPTO).